Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion

Brookline Capital Markets Analyst Recommendations & Stock Picks

View the latest stock recommendations issued by analysts at Brookline Capital Markets. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Brookline Capital Markets' equity research team. MarketBeat is not affiliated with or endorsed by Brookline Capital Markets.

  • Updated 5/20/2026
Average Return
00.00% 12-Month ROI
Total Ratings
2 Last 12 Months
Buy Ratings
2 Last 12 Months
Sell Ratings
0 Last 12 Months
Companies Covered
2 Last 12 Months
MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetails
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$10.98
5/20/2026 UpgradeStrong-BuyView details for Brookline Capital Markets rating of Promis Neurosciences (NASDAQ:PMN) on 5/20/2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$11.99
5/7/2026 Initiated Coverage$30.00BuyView details for Brookline Capital Markets rating of Ernexa Therapeutics (NASDAQ:ERNA) on 5/7/2026

MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Markets and other research firms in the last 90 days. Vote "Outperform" if you believe Brookline Capital Markets's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Brookline Capital Markets's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.
COMMUNITY RATINGS
2.7out of 5 (last 90 days)
2.7 of 5 stars
OUTPERFORM VOTES
30 Believe will outperform the market
UNDERPERFORM VOTES
26 Believe will underperform the market

Brookline Capital Markets Stock Coverage by Sector

Brookline Capital Markets concentrates its research most heavily in Medical (100.0%). The chart below shows how Brookline Capital Markets' 2 rated companies are distributed across all 1 sector it covers.

Brookline Capital Markets - Frequently Asked Questions

Brookline Capital Markets' analysts currently have buy-equivalent ratings on 2 companies. Recent upgrades to buy include Promis Neurosciences.

Brookline Capital Markets has the deepest coverage in Medical (100.0% of rated companies).

Brookline Capital Markets issued 2 ratings over the last 12 months across 2 companies — an average of roughly 0 rating actions per month. These include initiated coverage and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current Brookline Capital Markets analyst actions.